Please note Epocrates will no longer provide this CME offering after December 31, 2015. However this free offering will continue to be available directly from RealCME and there will be no interruption to your account, including credits, certificates and new course offerings.

Please directly access your account by clicking RealCME Health Professional and use the same email address to log in to your account that you have used with EpocratesCME. For security purposes, you will be asked to establish a new password.

If you have already created a password, you may return to RealCME Health Professional anytime and continue to participate in this great variety of CME activities.

An Update on Comparative Effectiveness in DMARDS for RA


An Update on Comparative Effectiveness in DMARDS for RA

Topic: Rheumatology
Relevant Terms: RA, Rheumatoid Arthritis, Rheumatology
Primary Audience: This activity is intended for rheumatologists involved in the management of patients with moderate to severe rheumatoid arthritis
Launch Date: 12-Jun-14
Credits: 0.5 AMA PRA Category 1 Credit
0.5 AAPA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Rheumatoid Arthritis: A Clinical Update on the Comparative Effectiveness of Biological DMARDs

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Explain the concept of "comparative effectiveness"
  2. Summarize the comparative effectiveness trials of biological DMARDs for the treatment of RA
  3. Compare and contrast the issues of treatment safety in managing RA


    Vivian P. Bykerk, BSc, MD, FRCPC
    Director of Research
    Director of the Inflammatory Arthritis Center for Excellence Hospital for Special Surgery
    New York, NY
    Jonathan Kay, MD
    Director of Clinical Research, Division of Rheumatology
    Professor of Medicine
    University of Massachusetts Medical School
    Worcester, MA
    Elena M. Massarotti, MD
    Center for Clinical Therapeutics
    Rheumatology Director, Clinical Trials
    Lupus Center Division of Rheumatology Brigham and Women's Hospital
    Boston, MA
    Michael O. Fleming, MD, FAAFP
    Assistant Clinical Professor of Family Medicine and Comprehensive Care
    LSU Health Science Center School of Medicine
    Shreveport, LA
    Assistant Clinical Professor of Family Medicine
    Department of Family and Community Medicine, Tulane University Medical School
    New Orleans, LA
    Chief Medical Officer
    Antidote Education Company & Amedisys, Inc.
    Dallas, TX
    Antidote is committed to creating, developing, and operating high-quality, relevant, and practical continuing medical education activities that are in compliance with the ACCME's policies on commercial support and disclosure. Specifically, we are dedicated to ensuring that our activities are planned and implemented free of the control of commercial interests. To this end, Antidote requires everyone who is in a position to influence the content of an activity to disclose all relevant relationships with commercial interests.  Antidote then seeks to resolve these conflicts. Any person who refuses to disclose their relationships, or whose conflicts cannot be resolved may not participate in the activity. In addition, it is our standard practice to disclose all relevant financial relationships of our faculty in writing to our attendees before the beginning of an educational activity.

    Antidote also requires that faculty disclose to the participants when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

    The planning staff of Antidote Medical Education Company, and RealCME have no commercial relationships to disclose.
    Individuals in a position to control the content of this activity reported the following relevant financial relationships with commercial interests:
    Elena M. Massarotti, MD has disclosed the following relationships:
    Consulting Fee(s): Sanofi Aventis, Biogen
    Research/Grant(s): Bristol-Myers Squibb, Human Genome Sciences
    Jonathan Kay, MD has disclosed the following relationships:
    Honorarium: Pfizer
    Consulting Fee(s): Bristol-Myers Squibb
    Research/Grant(s): Abbott Laboratories, Eli Lilly, Pfizer, Sanofi-Aventis
    Vivian P. Bykerk, BSc, MD, FRCPC has disclosed the following relationships:
    Honorarium: Bristol-Myers Squibb
    Consulting Fee(s): Amgen, Augurex, Crescendo, Gennentech, Merck, Pfizer, Roche, UCB
    Research/Grant(s): Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Gennentech, Johnson & Johnson, Pfizer, Roche, UCB
    Other: Data Safety Monitoring Board, Spouse Novartis Employee and owns stock

    The following individuals have indicated no conflict of interest disclosures to report:
    Michael O. Fleming, MD FAAFP (Course Director)
    Leigh McKinney (Editor)
    Matthew Fleming (Vice President, Antidote Education Company)
    All faculty have indicated that this enduring material does not include the off-label/investigational use of a commercial product or device. 
    The opinions and recommendations expressed by faculty in this activity are their own and do not necessarily represent the views of Antidote Education Company, and RealCME. Please review complete prescribing information for specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

    ACCME: Antidote Education Company is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Antidote designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.50 hours of Category I credit for completing this program.
    There are no fees for participating in and receiving credit for this activity. The participant must read the learning objectives and enduring material and must answer the multiple-choice online post-test. Please complete the evaluation form, which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs. A score of at least 65% is required to successfully complete this activity. The participant may take the test until successfully passed. Credit is available through August 19, 2015.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above

    Release Date:  June 12, 2014 
    Expiration Date:  August 19, 2015
    Copyright © 2014 -2015 Antidote Education Company. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
    Please read Antidote's Privacy Policy at
    If you have questions about this CME activity, please Antidote at 888-692-2631 or
    This activity is made possible by an educational grant from Bristol-Myers Squibb.